Favorable Benefit Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNFNave or TNFFailure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology

OSAKA Japan Sept. 16 2016 PRNewswire Takeda Pharmaceutical Company Limited TSE 4502 "Takeda" announced that an exploratory analysis of the GEMINI 1 data evaluating Entyvio&160;vedolizumab&160;therapy in patients with ulcerative colitis U...